Loading
Adding pembrolizumab to first-line chemotherapy lengthened survival by almost seven months in advanced triple-negative breast cancer whose tumours had a PD-L1 combined positive score of 10 or more.
Phase 3 placebo-controlled trial of 847 patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer randomised 2:1 to pembrolizumab or placebo with nab-paclitaxel, paclitaxel or gemcitabine-carboplatin.
In patients with a combined positive score of 10 or more, median overall survival was 23.0 versus 16.1 months (hazard ratio 0.73); no significant benefit was seen at lower PD-L1 scores.
PD-L1 testing with the combined positive score decides first-line treatment in metastatic triple-negative breast cancer; pembrolizumab-chemotherapy is the standard for scores of 10 or more.
Shares Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance, KEYNOTE-355, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Metastatic triple-negative breast cancer.
Shares KEYNOTE-355, Metastatic triple-negative breast cancer, PD-L1, Pembrolizumab.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Pembrolizumab.
Shares KEYNOTE-355, PD-L1 CPS (combined positive score), PD-L1, Pembrolizumab.
Shares Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance, KEYNOTE-355, PD-L1 CPS (combined positive score), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, PD-L1, New England Journal of Medicine.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Metastatic triple-negative breast cancer, New England Journal of Medicine.